Effects of Lidocaine, Dexmedetomidine, and Their Combination on TNF-a Following Laparoscopic Cholecystectomy

Effects of Intravenous Lidocaine, Dexmedetomidine, and Their Combination on TNF-a in Patients Undergoing Laparoscopic Cholecystectomy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190325043107N59

Enrollment

320

Registered

2025-08-08

Start date

2025-09-02

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor Necrosis Factor Alpha. Inflammatory and immune myopathies, not elsewhere classified

Interventions

Intervention 1: Intervention group: Patients in this group receive a 2% lidocaine bolus at a dose of 1.5 mg/kg over 10 minutes before anesthesia induction, followed by a continuous lidocaine infusion

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: ASA physical status class I and II according to the American Society of Anesthesiologists Age between 18 and 65 years Undergoing laparoscopic cholecystectomy under general anesthesia

Exclusion criteria

Exclusion criteria: History of allergy to local anesthetics and dexmedetomidine Preoperative atrioventricular block Preoperative bradycardia

Design outcomes

Primary

Measure	Time frame
Tumor Necrosis Factor Alpha. Timepoint: Before the intervention, during anesthesia, and 24 hours after the completion of surgery. Method of measurement: Venous blood sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Khanbabayi Gol

Tabriz University of Medical Sciences

Khanbabayimehdi69@gmail.com+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026